These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Stevens-Johnson syndrome/toxic epidermal necrolysis after initiation of carbamazepine in a HLA-B*15:02 gene carrier – screening in risk patients is recommended].
    Author: Anastasopoulou S, Komuda M, Presman B, Karlsson M, Tomson T.
    Journal: Lakartidningen; 2017 Feb 21; 114():. PubMed ID: 28221394.
    Abstract:
    Stevens-Johnson syndrome/toxic epidermal necrolysis after initiation of carbamazepine in a HLA-B*15:02 gene carrier - screening in risk patients is recommended A 32-year-old woman, adopted from Indonesia, developed Stevens-Johnsons syndrome (SJS)/toxic epidermal necrolysis (TEN) after initiating carbamazepine treatment for epilepsy. SJS and TEN are rare but life-threatening adverse effects of carbamazepine, with a 72-100% risk of occurrence in patients carrying the HLA-B*15:02 allele. The HLA-B*15:02 allele is common in several Asian groups but less prevalent in European populations. Screening for HLA-B*15:02, or choice of medication other than aromatic anticonvulsants in patients with Asian ancestry, is recommended when treatment with carbamazepine is considered.
    [Abstract] [Full Text] [Related] [New Search]